Arcturus Offering Monday, November 16, 2026 +0.80 Positive

Arcturus Announces $50M Investment from Meiji Seika Pharma

Arcturus Therapeutics receives $50 million from Meiji Seika Pharma at an 80% premium. Proceeds will fund ARCT-2601 and validate the LUNAR 2.0 platform amid expanding collaborations with Japanese partners.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed